tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Kennen Mackay, 131 are a BUY (67.53%), 62 are a HOLD (31.96%), 1 are a SELL (0.52%).
Analyst Kennen Mackay, carries an average stock price target met ratio of 58.64% that have a potential upside of 22.55% achieved within 192 days. Previously, Kennen Mackay worked at RBC.
Kennen Mackay’s has documented 386 price targets and ratings displayed on 26 stocks. The coverage was on the Healthcare sector.
Most recent stock forecast was given on EXEL, Exelixis at 16-Oct-2024.
Analyst best performing recommendations are on ANAB (ANAPTYSBIO).
The best stock recommendation documented was for ANAB (ANAPTYSBIO) at 4/4/2018. The price target of $86 was fulfilled within 2 days with a profit of $8.35 (8.85%) receiving and performance score of 44.25.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
$15
$10.4 (226.09%)
$15
4 months 23 days ago
(25-Nov-2024)
0/6 (0%)
$9.06 (152.53%)
Buy
$18
$13.4 (291.30%)
$18
5 months 19 days ago
(29-Oct-2024)
1/5 (20%)
$11.43 (173.97%)
61
Hold
$6
$1.4 (30.43%)
$25
2 years 5 months 3 days ago
(14-Nov-2022)
1/2 (50%)
$1.85 (44.58%)
452
Buy
$75
$70.79 (1681.47%)
$50
4 years 5 months 7 days ago
(11-Nov-2020)
2/3 (66.67%)
$45.92 (117.11%)
101
Buy
$22
4 years 11 months 9 days ago
(08-May-2020)
1/3 (33.33%)
$-59.25 (-72.92%)
820
What Year was the first public recommendation made by Kennen Mackay?
